BusinessTimes.top
BusinessTimes is for folks who likes to get updated before others about latest news of Stock Markets, Business News, Personal Funds, Currencies and Much More. If you have any kind of questions, please feel free to ask by contacting us.

Add Up The Pieces: The First Trust Health Care AlphaDEX Fund ETF Could Be Worth $85

<div innerhtml="

Getty

Getty

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.&nbsp; For the First Trust Health Care AlphaDEX Fund ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $85.29 per unit.

With FXH trading at a recent price near $72.40 per unit, that means that analysts see 17.81% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FXH’s underlying holdings with notable upside to their analyst target prices are Mylan, Jazz Pharmaceuticals and Alexion Pharmaceuticals. Although MYL has traded at a recent price of $26.44/share, the average analyst target is 40.75% higher at $37.21/share. Similarly, JAZZ has 38.26% upside from the recent share price of $129.42 if the average analyst target price of $178.94/share is reached, and analysts on average are expecting ALXN to reach a target price of $164.62/share, which is 26.54% above the recent price of $130.09.

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
First Trust Health Care AlphaDEX Fund ETF FXH $72.40 $85.29 17.81%
Mylan NV MYL $26.44 $37.21 40.75%
Jazz Pharmaceuticals plc JAZZ $129.42 $178.94 38.26%
Alexion Pharmaceuticals Inc. ALXN $130.09 $164.62 26.54%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock’s trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

Click here to find out 10 ETFs With Most Upside To Analyst Targets &raquo;

” readability=”34.647252231094″>

Getty

Getty

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.  For the First Trust Health Care AlphaDEX Fund ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $85.29 per unit.

With FXH trading at a recent price near $72.40 per unit, that means that analysts see 17.81% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FXH’s underlying holdings with notable upside to their analyst target prices are Mylan, Jazz Pharmaceuticals and Alexion Pharmaceuticals. Although MYL has traded at a recent price of $26.44/share, the average analyst target is 40.75% higher at $37.21/share. Similarly, JAZZ has 38.26% upside from the recent share price of $129.42 if the average analyst target price of $178.94/share is reached, and analysts on average are expecting ALXN to reach a target price of $164.62/share, which is 26.54% above the recent price of $130.09.

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
First Trust Health Care AlphaDEX Fund ETF FXH $72.40 $85.29 17.81%
Mylan NV MYL $26.44 $37.21 40.75%
Jazz Pharmaceuticals plc JAZZ $129.42 $178.94 38.26%
Alexion Pharmaceuticals Inc. ALXN $130.09 $164.62 26.54%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock’s trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

Click here to find out 10 ETFs With Most Upside To Analyst Targets »

You might also like

Comments are closed.